Hormone receptor positive postmenopausal early breast cancer after adjuvant tamoxifen

Hormone receptor-positive postmenopausal early breast cancer after adjuvant tamoxifen refers to a clinical state in postmenopausal women with localized or regional breast carcinoma whose tumor cells express estrogen or progesterone receptors, and who have completed an initial course of adjuvant endocrine therapy with tamoxifen

Hormone receptor-positive postmenopausal early breast cancer after adjuvant tamoxifen refers to a clinical state in postmenopausal women with localized or regional breast carcinoma whose tumor cells express estrogen or progesterone receptors, and who have completed an initial course of adjuvant endocrine therapy with tamoxifen Pathophysiologically, these early-stage tumors depend on estrogen-mediated signaling pathways to promote cell proliferation and survival Following initial selective estrog...

Pathophysiologically, these early-stage tumors depend on estrogen-mediated signaling pathways to promote cell proliferation and survival Following initial selective estrogen receptor modulator therapy with tamoxifen, this clinical stage is characterized by a continued risk of late micrometastatic recurrence or contralateral primary disease, defining a population eligible for sequential or extended adjuvant endocrine therapy

In the postmenopausal setting, circulating estrogens are primarily synthesized via peripheral aromatization of adrenal androgens rather than ovarian production

In the postmenopausal setting, circulating estrogens are primarily synthesized via peripheral aromatization of adrenal androgens rather than ovarian production Following initial selective estrogen receptor modulator therapy with tamoxifen, this clinical stage is characterized by a continued risk of late micrometastatic recurrence or contralateral primary disease, defining a population eligible for sequential or extended adjuvant endocrine therapy